Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Merck & Co., Inc. (NYSE: MRK) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. Merck is a New Jersey–incorporated biopharmaceutical preparation manufacturer whose common stock and multiple series of notes are registered on the New York Stock Exchange, as reflected in its Form 8-K filings.
Through this page, readers can review Merck’s current and historical filings, including Form 8-K reports on material events such as public offerings of long-dated notes under its automatic shelf registration statement on Form S-3ASR and announcements of restructuring programs. Filings related to quarterly and annual results, such as earnings releases furnished on Form 8-K, give additional context on the company’s financial condition and performance.
For a research-intensive company like Merck, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) are key sources for information on its human health and animal health businesses, major products like KEYTRUDA and GARDASIL, pipeline programs including WINREVAIR and Alzheimer’s disease candidates, risk factors and capital structure. Forms 3, 4 and 5, when filed, provide details on insider transactions by directors and officers.
Stock Titan enhances these filings with AI-generated explanations that highlight important sections, clarify technical language and point out items that may interest investors, such as new debt issuances, restructuring charges or significant acquisitions. Real-time updates from EDGAR help ensure that newly filed Merck documents, including 10-Ks, 10-Qs and Form 4 insider reports, appear promptly, allowing users to track regulatory disclosures related to MRK in a single, organized feed.
Merck & Co., Inc. executive Zachary Jennifer, EVP and General Counsel, reported new equity compensation awards. She received stock options for 35,312 shares of common stock at an exercise price of $113.15 per share, vesting in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029, and expiring on 5/4/2036. She was also granted 12,064 restricted stock units, each representing a contingent right to one share of common stock, vesting and distributing in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. Following these awards, she directly holds 70,897.254 shares of Merck common stock.
Merck & Co., Inc. executive vice president and Chief Information & Digital Officer David Michael Williams reported new equity awards. He received stock options on 13,582 shares of common stock at an exercise price of $113.15 per share and 4,640 restricted stock units, both vesting in three equal installments from 2027 to 2029. Following these awards, his directly held common stock position is reported as 31,716.037 shares.
Merck & Co., Inc. EVP & CFO Caroline Litchfield reported new equity awards in the form of stock options and restricted stock units. She now directly holds 92,300.657 shares of Merck common stock.
She received stock options for 46,566 shares at an exercise price of $113.15 per share, vesting in three equal installments on May 5, 2027, 2028, and 2029, and expiring on May 4, 2036. She also received 15,908 restricted stock units, each representing a right to one Merck share, vesting and settling in shares in three equal installments on May 5, 2027, 2028, and 2029.
Merck & Co., Inc. Executive VP & President, MRL, Dean Y. Li reported new equity awards. The filing shows a grant of 58,207 stock options with a $113.15 exercise price and a separate grant of 19,885 restricted stock units, each tied to one share of Merck common stock.
The options vest and become exercisable in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029, and expire on 5/4/2036. The restricted stock units vest and are delivered as shares on the same three annual dates. Following these transactions, Li directly holds 94,431.0500 shares of Merck common stock.
Merck & Co., Inc. executive Betty D. Larson, EVP and Chief HR Officer, reported equity awards and updated her holdings. She now directly holds 13,774 shares of Merck common stock.
On 5/5/2026, she received a grant of 23,283 stock options with an exercise price of $113.15 per share, expiring on 5/4/2036. These options vest in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
She was also granted 7,954 restricted stock units, each representing one share of common stock. These RSUs vest and are distributed in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029.
Merck & Co., Inc. executive Richard R. DeLuca, EVP & President of Merck Animal Health, reported compensation-related equity grants rather than open-market trades. He received 34,924 stock options with an exercise price of $113.15 per share, which vest in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029, and expire on 5/4/2036.
DeLuca also received 11,931 restricted stock units, each representing one share of Merck common stock, vesting and settling in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. Following these grants, he holds 161,537.0700 common shares directly and 1,320.9907 shares indirectly through a 401(k) plan.
Merck & Co., Inc. Chairman, CEO & President Robert M. Davis reported new equity awards and updated his shareholdings. He now holds 450,350.757 shares of common stock directly. On May 5, 2026, he was granted 139,697 stock options with an exercise price of $113.15 per share, vesting in three equal installments on May 5, 2027, 2028 and 2029. He also received 47,724 restricted stock units, each representing a right to one Merck common share, vesting and settling in three equal installments on May 5, 2027, 2028 and 2029.
Merck & Co., Inc. reported that EVP, Specialty, Pharma, & ID Brian Foard received new equity awards. On May 5, 2026, he was granted a stock option covering 31,044 shares of common stock with an exercise price of $113.15 per share, vesting in three equal annual installments on May 5 of 2027, 2028, and 2029.
He was also granted restricted stock units for 35,351 shares and an additional 10,605 shares. Each restricted stock unit represents a contingent right to receive one share of Merck common stock and vests, with shares distributed, in three equal installments on May 5, 2027, May 5, 2028, and May 5, 2029. These are compensation grants, not open-market purchases or sales.
Merck & Co., Inc. executive David R. Maraldo reported new equity awards and updated holdings. As EVP & Pres. MMD, he received a grant of stock options for 21,731 shares of common stock at an exercise price of $113.15 per share, vesting in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. He also received 7,424 restricted stock units, each representing a contingent right to one Merck common share, vesting and settling in three equal installments on those same dates. Following these transactions, he reports direct ownership of 18,212.434 shares of common stock and indirect ownership of 8,359.14 shares through a 401(k) plan.
Oosthuizen Johannes Jacobus reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. executive vice president for Oncology & International, Johannes Jacobus Oosthuizen, reported new equity awards. He received a grant of 31,044 stock options, each allowing him to buy Merck common stock at $113.15 per share, expiring in 2036 and vesting in three equal installments on 5/5/2027, 5/5/2028, and 5/5/2029. He was also granted 10,605 restricted stock units, each representing a right to receive one Merck share, vesting and settling in stock in three equal installments on the same dates. Following these awards, he directly holds 21,895.389 shares of Merck common stock.